Advertisement

Loading...

Alphamab Oncology

9966.HKHKSE
Healthcare
Biotechnology
HK$8.91
HK$1.11(14.23%)
Hong Kong Market is Open • 10:06

Alphamab Oncology (9966.HK) Stock Competitors & Peer Comparison

See (9966.HK) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
9966.HKHK$7.82+1.56%7.7B-56.64-HK$0.14N/A
6160.HKHK$170.60-1.95%257B115.61HK$1.48N/A
1801.HKHK$84.90-0.70%148.2B162.45HK$0.53N/A
2269.HKHK$33.02+2.04%129.6B23.94HK$1.31N/A
9926.HKHK$130.20+3.01%122.4B-122.11-HK$1.09N/A
1177.HKHK$5.88-0.17%104.6B39.00HK$0.15+1.54%
1530.HKHK$22.64-5.59%57.3B22.28HK$1.09+1.03%
9995.HKHK$95.80+1.75%54.4B67.71HK$1.46N/A
3759.HKHK$18.72+1.03%49.9B18.84HK$0.97+1.20%
2696.HKHK$69.75-2.72%37.9B40.73HK$1.71N/A
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

9966.HK vs 6160.HK Comparison April 2026

9966.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 9966.HK stands at 7.7B. In comparison, 6160.HK has a market cap of 257B. Regarding current trading prices, 9966.HK is priced at HK$7.82, while 6160.HK trades at HK$170.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

9966.HK currently has a P/E ratio of -56.64, whereas 6160.HK's P/E ratio is 115.61. In terms of profitability, 9966.HK's ROE is -0.06%, compared to 6160.HK's ROE of +0.07%. Regarding short-term risk, 9966.HK is more volatile compared to 6160.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 9966.HK.Check 6160.HK's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions